Abstract:Objective: This study aims to analyze the efficacy of anti-syphilis treatment and the impact of syphilis events on HIV virology and immunology in HIV/syphilis co-infected patients on long-term antiretroviral therapy (ART) and to investigate the incidence and factors of syphilis recurrence/re-infection/serofast state. The insights derived from this investigation can potentially guide strategies for preventing and managing syphilis and AIDS. Methods: A retrospective case–control study was conducted at the AIDS clinic of Peking Union Medical College Hospital from January 2003 to December 2022. The study involved 86 HIV/syphilis co-infected patients and 86 HIV mono-infected patients matched based on age, baseline CD4 + T cell counts, and viral load. We examined the clinical characteristics of HIV/syphilis co-infected patients, evaluated the efficacy of anti-syphilis treatment, and analyzed the dynamic changes in HIV virology and immunology. The Generalized Estimating Equations (GEE) model investigated the factors associated with HIV/syphilis co-infection and syphilis recurrence/reinfection/serofast state. Results: Syphilis serofast state was observed in 11.6% (10/86) of HIV/syphilis co-infected patients after treatment, and 33.7% (29/86) had syphilis recurrence or re-infection. The overall effectiveness of syphilis treatment stood at 76.8% (63/82). Notably, the effectiveness of syphilis treatment displayed a significant correlation with baseline syphilis titers exceeding 1:128 ( p = 0.003). Over the 10-year follow-up period on ART, the HLA-DR + CD8+/CD8 + % levels in the HIV/syphilis co-infected group were markedly higher than those in the HIV mono-infected group ( p < 0.05). However, no significant differences were observed between the two groups regarding HIV viral load, CD4+ T cell counts, CD8+ T cell counts, CD4/CD8 ratio, and CD38 + CD8+/CD8 + % ( p > 0.05). GEE analysis model revealed that elevated HLA-DR + CD8+/CD8 + % levels were associated with HIV/syphilis co-infection (OR = 1.026, 95% CI = 1.007–1.046; p = 0.007) and syphilis recurrence/reinfection/serofast state (OR = 1.036, 95% CI = 1.008–1.065; p = 0.012). Conclusion: While HIV/syphilis co-infected patients typically receive adequate treatment, the incidence of syphilis recurrence and reinfection remain notably elevated. A heightened HLA-DR + CD8+/CD8+ % is a notable risk factor for HIV/syphilis co-infection and syphilis recurrence/reinfection/serofast state. Therefore, it is advisable to reinforce health education efforts and ensure regular follow-ups for people living with HIV undergoing ART to monitor syphilis infection or increased risk of syphilis infection.

Comparisons of Serologic Responses of Early Syphilis to Treatment with a Single-Dose Benzathine Penicillin G Between HIV-Positive and HIV-Negative Patients

Higher serologic responses of early syphilis to single-dose benzathine penicillin G plus doxycycline versus single-dose benzathine penicillin G alone among people with HIV

One Dose versus Three Weekly Doses of Benzathine Penicillin G for Patients Co-Infected with HIV and Early Syphilis: A Multicenter, Prospective Observational Study

The Tradition Algorithm Approach Underestimates the Prevalence of Serodiagnosis of Syphilis in HIV-infected Individuals

The effect of syphilis treatment during pregnancy on serological test results in infants born to syphilis mothers

Azithromycin Versus Penicillin G Benzathine for Early Syphilis

A Multicenter Study Evaluating Ceftriaxone and Benzathine Penicillin G as Treatment Agents for Early Syphilis in Jiangsu, China

Azithromycin Compared with Penicillin G Benzathine for Treatment of Incubating Syphilis

A Randomized, Comparative Pilot Study of Azithromycin Versus Benzathine Penicillin G for Treatment of Early Syphilis

Comparing Noninvasive Predictors of Neurosyphilis among Syphilis Patients with and Without HIV Co-Infection Based on the Real-World Diagnostic Criteria: A Single-Center, Retrospective Cohort Study in China.

Azithromycin Vs. Benzathine Penicillin G for Early Syphilis: a Meta-Analysis of Randomized Clinical Trials

A 4-fold or greater decrease in TPPA titers may indicate effective BPG treatment in primary syphilis

Clinical and immunological characteristics of HIV/syphilis co-infected patients following long-term antiretroviral treatment

Efficacy of minocycline in the treatment of early syphilis

Clinical Characteristics, Diagnosis, and Predictors of Neurosyphilis Patients with Human Immunodeficiency Virus Co-Infection

Characteristics of Serologic Resistance in Syphilis Patients with Latent Blood-Transmitted Risk

Syphilis Treatment: Systematic Review and Meta-Analysis Investigating Non-Penicillin Therapeutic Strategies

Effect of Procaine Benzylpenicillin on Early Syphilis

[WR in patients with secondary syphilis and HIV infection]

Further evaluation of the characteristics of Treponema pallidum–specific IgM antibody in syphilis serofast reaction patients

Combination of Amoxicillin 3,000 mg and Probenecid versus 1,500 mg Amoxicillin Monotherapy for Treating Syphilis in Patients with HIV: an Open-Label, Randomized, Controlled, Non-Inferiority Trial.